A new study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. When researchers treated a tumor grown from this sample with the drugs ...

EML4-ALK is a fusion-type protein tyrosine kinase that is present in 4 to 5% of cases of non–small-cell lung cancer and is generated as a result of a small inversion within the short arm of ...

In addition to detecting common EML4-ALK fusions, liquid biopsy was also able to detect resistance mechanisms like MET amplifications and discover novel fusion partners, including a patient with a ...

PURPOSEIn GI cancers, anaplastic lymphoma kinase (ALK) rearrangements are extremely less frequent than in non–small-cell lung cancer but may be important to offer personalized strategies of treatment ...

In this special issue of CURE, we examine some of the latest developments in the treatment of ALK-positive non-small cell lung cancer (NSCLC). This subtype of lung cancer, representing about 5% of ...

Did your doctor tell you that you have “stage IV lung cancer with ALK rearrangement”? Find out what that means.

Initial diagnosis of ALK -positive NSCLC often occurs in younger patients. 3 In 2020, cancer statistics from the Surveillance, Epidemiology, and End Results (SEER) Program showed that the median ...

The chromosomal rearrangements that interrupt the ALK gene and fuse it with another gene result in the creation of oncogenic ALK fusion genes. In turn, these enhance cell proliferation and survival.

Further, researchers have identified at least 13 known variants of the EML4-ALK fusion gene, a characteristic often cited as diagnostically problematic, especially given the rareness of ALK ...

Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such tumors. We explored the ...